Elacestrant (Korserdu, Menarini Stemline) is indicated for 'the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor'.
The dosage schedule is available in the summary of product characteristics for elacestrant.
The list price for elacestrant is £7,340 per 28 pack of 345-mg tablets and £2,447 per 28 pack of 86-mg tablets (excluding VAT; company submission).
The company has a commercial arrangement. This makes elacestrant available to the NHS with a discount. The size of the discount is commercial in confidence.